nach oben

Erschienen in:

02.02.2021 | Original Article

Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma

verfasst von: Liudmila V. Fedorova, Kirill V. Lepik, Natalia B. Mikhailova, Elena V. Kondakova, Yuri R. Zalyalov, Vadim V. Baykov, Elena V. Babenko, Andrey V. Kozlov, Ivan S. Moiseev, Boris V. Afanasyev

Erschienen in: Annals of Hematology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Immune checkpoint inhibitors (ICI) have demonstrated high therapeutic efficacy in relapsed or refractory classical Hodgkin lymphoma (r/r cHL). Nevertheless, despite the accumulated data, the question of the ICI therapy duration and efficacy of nivolumab retreatment remains unresolved. In this retrospective study, in a cohort of 23 adult patients with r/r cHL who discontinued nivolumab in complete response (CR), the possibility of durable remission achievement (2-year PFS was 55.1%) was demonstrated. Retreatment with nivolumab has demonstrated efficacy with high overall response rate (ORR) and CR (67% and 33.3% respectively). At the final analysis, all patients were alive with median PFS of 16.5 months. Grade 3–4 adverse events (AEs) were reported in 36% of patients, and there was no deterioration in terms of nivolumab retreatment–associated complications.

Nur mit Berechtigung zugänglich

Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, de Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM (2018) Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 36(14):1428–1439. https://doi.org/10.1200/JCO.2017.76.0793CrossRefPubMedPubMedCentral

Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH, for the KEYNOTE-087 (2017) KEYNOTE-087. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 35(19):2125–2132. https://doi.org/10.1200/JCO.2016.72.1316CrossRefPubMedPubMedCentral

Gauci M, Lanoy E, Champiat S, Caramella C et al (2019) Long-term survival in patients responding to anti-PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation. Clinical Cancer Research 25(3):946–956. https://doi.org/10.1158/1078-0432.ccr-18-0793CrossRefPubMed

Tachihara M, Negoro S, Inoue T, Tamiya M, Akazawa Y, Uenami T, Urata Y, Hattori Y, Hata A, Katakami N, Yokota S (2018) Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316). BMC Cancer 18:946. https://doi.org/10.1186/s12885-018-4819-2CrossRefPubMedPubMedCentral

Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejberg L, Schmidt H, van Thienen JV, Haanen JBAG, Tiainen L, Svane IM, Mäkelä S, Seremet T, Arance A, Dummer R, Bastholt L, Nyakas M, Straume O, Menzies AM, Long GV, Atkinson V, Blank CU, Neyns B (2019) Discontinuation of anti-PD-antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Annals of Oncology 30(7):1154–1161. https://doi.org/10.1093/annonc/mdz110CrossRefPubMed

Myint ZW, Arays R, Raajasekar AKA, Wang P (2018) Long-term outcomes in patients after discontinuation of immune checkpoint inhibitors. J Clin Res Med 1(3):1–4. https://doi.org/10.1200/JCO.2018.36.15_suppl.e15086CrossRef

Atkinson VG, Ladwa R (2016) Complete responders to anti-PD1 antibodies. What happens when we stop? Ann Oncol 27(6):1116P. https://doi.org/10.1093/annonc/mdw379.11

Myint Z, Arays R, Raajasekar AKA, Huang B, Chen Q, Wang P (2018) Long-term outcomes in patients after discontinuation of PD1/PDL1 inhibitors. J Clin Oncol 36:e15086. https://doi.org/10.1200/JCO.2018.36.15_suppl.e15086CrossRef

Spigel DR, et al (2017) CHECKMATE153: Randomized results of continuous vs 1-year fixed-duration nivolumab in patients with advanced non-small cell lung cancer. Ann Oncol 28:5. Abstract 1297O. https://www.primeoncology.org/app/uploads/prime_activities/42584/VPS_Madrid_1297O_Lung_Spigel.pdf

10.

Manson G, Herbaux C, Brice P, Bouabdallah K, Stamatoullas A, Schiano JM, Ghesquieres H, Dercle L, Houot R, Lymphoma Study Association (2018) Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma. Blood 131:2856–2859. https://doi.org/10.1182/blood-2018-03-841262CrossRefPubMed

11.

Lepik K, Fedorova L, Mikhailova N et al (2019) Cessation of immune checkpoint inhibitors therapy in r/r Hodgkin lymphoma: should we consider HSCT? 45th Annual Meeting of the European Society for Blood and Marrow Transplantation, Abstract collection. Poster number A232

12.

Goodman A (2017) Retreatment with checkpoint inhibitors may be feasible for some patients with NSCLC. The ASCO post. https://www.ascopost.com/issues/july-10-2017/retreatment-with-checkpoint-inhibitors-may-be-feasible-for-some-patients-with-nsclc. Accessed 10 June 2017

13.

Santini FC, Rizvi H, Wilkins O, van Voorthuysen M, Panora E, Halpenny D, Kris MG, Rudin CM, Chaft JE, Hellmann MD (2017) Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy. J Clin Oncol 35(15):9012. https://doi.org/10.1200/JCO.2017.35.15_suppl.9012CrossRef

14.

Fujita K, Uchida N, Yamamoto Y, et al (2019) Retreatment with anti-PD-L1 antibody in advanced non-small cell lung cancer previously treated with anti-PD-1 antibodies. Anticancer Research 39(7):3917–3921. 10.21873/anticanres.13543

15.

Alaiwi SA, Martini DJ, Xie W et al (2019) Safety and efficacy of restarting immune checkpoint inhibitors (ICI) after immune-related adverse events (irAEs) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 37(7):652–652. https://doi.org/10.1200/JCO.2019.37.7_suppl.652CrossRef

16.

Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, Long GV, Menzies AM, Eroglu Z, Johnson DB, Shoushtari AN (2018) Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 29:250–255. https://doi.org/10.1093/annonc/mdx642CrossRefPubMed

17.

Lebbé C, Weber JS, Maio M, Neyns B, Harmankaya K, Hamid O, O'Day SJ, Konto C, Cykowski L, McHenry MB, Wolchok JD (2014) Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol 25:2277–2284. https://doi.org/10.1093/annonc/mdu441CrossRefPubMedPubMedCentral

18.

Chiarion-Sileni V, Pigozzo J, Ascierto PA, Simeone E, Maio M, Calabrò L, Marchetti P, de Galitiis F, Testori A, Ferrucci PF, Queirolo P, Spagnolo F, Quaglino P, Carnevale Schianca F, Mandalà M, di Guardo L, del Vecchio M (2014) Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. Br J Cancer 110:1721–1726. https://doi.org/10.1038/bjc.2014.126CrossRefPubMedPubMedCentral

19.

Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S, MDX010-20 investigators (2013) Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res 19:2232–2239. https://doi.org/10.1158/1078-0432.CCR-12-3080CrossRefPubMed

20.

Maiko N, Nakaya A, Kurata T, et al (2018) Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer. Oncotarget 9(64):32298–32304. 10.18632/oncotarget.25949

21.

Pellegrini C, Casadei B, Cellini C, Argnani L, Cavo M, Zinzani PL (2018) Sequential double bridging to transplant with diversified anti-PD1 monoclonal antibodies retreatment in relapsed Hodgkin lymphoma: a case report. J Cancer Sci Ther 10(6):149. https://doi.org/10.4172/1948-5956.1000534CrossRef

22.

Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Lin J, Kim E, Nahar A, Balakumaran A, Moskowitz CH (2019) Pembrolizumab in relapsed or refractory Hodgkin lymphoma: two-year follow-up of KEYNOTE-087. Blood. 134:1144–1153. https://doi.org/10.1182/blood.2019000324CrossRefPubMedPubMedCentral

23.

Lepik KV, Mikhailova NB, Moiseev IS, et al (2019) Nivolumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after ASCT and in ASCTnaïve patients. Leukemia & Lymphoma 1–4. https://doi.org/10.1080/10428194.2019.1573368

24.

Kozlov AV, Kazantzev IV, Iukhta TV, et al (2019) Nivolumab in pediatric Hodgkin’s lymphoma. CTT. 10.18620/ctt-1866-8836-2019-8-4-41-48

25.

Lepik KV, Fedorova LV, Kondakova EV et al (2020) A phase 2 study of nivolumab using a fixed dose of 40 mg (Nivo40) in patients with relapsed/refractory Hodgkin lymphoma. Hemasphere 4(5):480. 2020 https://doi.org/10.1097/HS9.0000000000000480

26.

Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, Zhang W, Gao Y, Jin Z, Zhou J, Jin C, Zou L, Qiu L, Li W, Yang J, Hou M, Zeng S, Zhang Q, Hu J, Zhou H, Xiong Y, Liu P (2019) Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (Orient-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol 6:e12–e19. https://doi.org/10.1016/S2352-3026(18)30192-3CrossRefPubMed

27.

Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, Li W, Yang H, Liu T, Wang Q, Lv F, Yang Y, Guo H, Yang L, Elstrom R, Huang J, Novotny W, Wei V, Zhu J (2018) Tislelizumab (Bgb-A317) for relapsed/refractory classical Hodgkin lymphoma: preliminary efficacy and safety results from a phase 2 study. Blood 132:682. https://doi.org/10.1182/blood-2018-99-117848CrossRef

28.

Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, Li X, Liu J, Ku W, Zhang Y, Chen M, An X, Shi L, Brock MV, Bai J, Han W (2019) Addition of low-dose decitabine to anti-Pd-1 antibody camrelizumab in relapsed/refractory classical Hodgkin lymphoma. J Clin Oncol 37:1479–1489. https://doi.org/10.1200/JCO.18.02151CrossRefPubMed

29.

Chen R, Gibb AL, Collins GP, Popat R, el-Sharkawi D, Burton C, Lewis D, Miall FM, Forgie A, Compagnoni A, Andreola G, Brar S, Thall A, Woolfson A, Radford J (2017) Blockade of the PD-1 checkpoint with anti–PD-L1 antibody Avelumab is sufficient for clinical activity in relapsed/refractory classical Hodgkin lymphoma (cHL). Hematol Oncol 35:67. https://doi.org/10.1002/hon.2437_54CrossRef

30.

Hamadani M, Collins GP, Samaniego F, Spira AI, Davies A, Radford J, Caimi P, Menne T, Boni J, Cruz H, Feingold J, He S, Wuerthner J, Horwitz SM (2018) Phase 1 study of Adct-301 (Camidanlumab Tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkin lymphoma. Blood 132:928. https://doi.org/10.1182/blood-2018-99-118198CrossRef

31.

Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, Dietlein M, Kuhnert G, Kessler J, Buerkle C, Ravic M, Knackmuss S, Marschner JP, Pogge von Strandmann E, Borchmann P, Engert A (2015) A phase 1 study of the bispecific anti-CD30/CD16A antibody construct Afm13 in patients with relapsed or refractory Hodgkin lymphoma. Blood 125:4024–4031. https://doi.org/10.1182/blood-2014-12-614636CrossRefPubMedPubMedCentral

32.

Smith SM, Schöder H, Johnson JL, et al (2013) The Anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: cancer and leukemia group B 50602 (Alliance) Leukemia & Lymphoma 54:1405–1410. 10.3109/10428194.2012.744453

33.

Freedman AS, Kuruvilla J, Assouline SE et al (2010) Clinical activity of lucatumumab (Hcd122) in patients (Pts) with relapsed/refractory Hodgkin or non-Hodgkin lymphoma treated in a phase Ia/II clinical trial (NCT00670592). Blood 116:284. https://doi.org/10.1182/blood.V116.21.284.284CrossRef

34.

Lepik KV, Mikhailova NB, Kondakova EV, Zalyalov YR, Fedorova LV, Tsvetkova LA, Kotselyabina PV, Borzenkova ES, Babenko EV, Popova MO, Darskaya EI, Baykov VV, Moiseev IS, Afanasyev BV (2020) A study of safety and efficacy of nivolumab and bendamustine (NB) in patients with relapsed/refractory Hodgkin lymphoma after nivolumab monotherapy failure. HemaSphere 4:e401. https://doi.org/10.1097/HS9.0000000000000401CrossRefPubMedPubMedCentral

Titel: Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma
verfasst von: Liudmila V. Fedorova
Kirill V. Lepik
Natalia B. Mikhailova
Elena V. Kondakova
Yuri R. Zalyalov
Vadim V. Baykov
Elena V. Babenko
Andrey V. Kozlov
Ivan S. Moiseev
Boris V. Afanasyev
Publikationsdatum: 02.02.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 3/2021
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-021-04429-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Novel tumour–infiltrating lymphocyte-related risk stratification based by flow cytometry for patients with de novo angioimmunoblastic T cell lymphoma

Supportive and palliative care in hemato-oncology: how best to achieve seamless integration and subspecialty development?

A multicenter phase II study of intrabone single-unit cord blood transplantation without antithymocyte globulin

Abatacept as salvage therapy in chronic graft-versus-host disease—a retrospective analysis

Coombs-negative hemolytic anemia and elevated plasma hemoglobin levels in COVID-19

Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis